CHCWM – Cancer & Hematology Centers of West Michigan

Abbvie (VERONA)

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)

Principal Investigator: Dr. Brett Brinker

For more information on this trial, read its profile on clinicaltrials.gov here.